Example: Heart Attack

Search clinical trials for: Interleukin-2

Total 602 results

NCT04562129

Recruiting

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Conditions: Melanoma Stage III; Melanoma Stage IV; Inoperable Disease
NCT04433585

Recruiting

A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)

Conditions: Systemic Lupus Erythematosus
NCT04426669

Recruiting

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

Conditions: Gastrointestinal Epithelial Cancer; Gastrointestinal Neoplasms; Cancer of Gastrointestinal Tract; Cancer, Gastrointestinal; Gastrointestinal Cancer; Colo-rectal Cancer; Pancreatic Cancer; Gall Bladder Cancer; Colon Cancer; Esophageal Cancer; Stomach Cancer
NCT04409080

Not yet recruiting

REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy

Conditions: Severe Aplastic Anemia (SAA)
NCT04397107

Recruiting

The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases

Conditions: Systemic Lupus Erythematosus
NCT04387942

Recruiting

The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura

Conditions: Purpura, Schoenlein-Henoch
NCT04365985

Recruiting

Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19

Conditions: COVID-19; Acute Respiratory Distress Syndrome; Severe Acute Respiratory Syndrome (SARS); Coronavirus Infections
NCT04354025

Not yet recruiting

Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML

Conditions: Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia
NCT04279613

Not yet recruiting

TN27: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

Conditions: Type I Diabetes
NCT04263831

Not yet recruiting

LOW DOSE IL-2 FOR THE TREATMENT OF CROHN'S DISEASE

Conditions: Crohn Disease
NCT04241601

Not yet recruiting

Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes - IVORY

Conditions: Acute Coronary Syndromes
NCT04237987

Not yet recruiting

Low-dose Interleukin-2 in Combination With Standard Therapy on Idiopathic Inflammatory Myopathy

Conditions: Inflammatory Myopathy
NCT04217473

Recruiting

TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma

Conditions: Metastatic Melanoma
NCT04209712

Recruiting

Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease

Conditions: Acute Myeloid Leukemia
NCT04165967

Not yet recruiting

Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma

Conditions: Advanced Melanoma
NCT04166006

Recruiting

A Phase II Study on Adjuvant Vaccination With Dendritic Cells Loaded With Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.

Conditions: Head Neck Tumors; Neuroendocrine Tumors; Soft Tissue Sarcoma; Rare Cancer; Vaccination
NCT04155710

Recruiting

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
NCT04144517

Recruiting

A Study of ALKS 4230 With Pembrolizumab in Head and Neck Cancer

Conditions: Non-cutaneous Squamous Cell Carcinoma of Head and Neck
NCT04131231

Not yet recruiting

Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion

Conditions: Lung Cancer; Breast Cancer; Malignant Pleural Effusion
NCT04119024

Suspended

Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma

Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8; IL13RA2 Positive; Metastatic Melanoma; Cutaneous Melanoma, Stage III; Cutaneous Melanoma, Stage IV
NCT04111510

Recruiting

Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer

Conditions: Metastatic Triple Negative Breast Cancer
NCT04077684

Recruiting

Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled Trial

Conditions: Systemic Lupus Erythematosus
NCT04077736

Not yet recruiting

Low-dose Recombinant Human IL-2 for the Treatment of Relapsing Polychondritis

Conditions: Relapsing Polychondritis
NCT04062006

Not yet recruiting

Low-dose Interleukin-2 Treatment on Polymyalgia Rheumatica

Conditions: Polymyalgia Rheumatica
NCT04062019

Not yet recruiting

Low-dose Interleukin-2 Treatment on Idiopathic Inflammatory Myopathy

Conditions: Inflammatory Myopathy
NCT04058028

Recruiting

Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)

Conditions: Systemic Lupus Erythematosus (SLE)
NCT04055623

Active, not recruiting

T-regulatory Cells in ALS

Conditions: ALS (Amyotrophic Lateral Sclerosis)
NCT04052334

Recruiting

Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma

Conditions: Sarcoma
NCT04023149

Recruiting

Efficacy of Interleukin-2 Gargle in the Treatment of Oral Mucosa Lesion in Pemphigus Vulgaris

Conditions: Pemphigus Vulgaris
NCT04011033

Recruiting

Study of Adoptive Transfer of iNKT Cells Combined With TACE to Treat Advanced HCC

Conditions: Hepatocellular Carcinoma
NCT04009681

Recruiting

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors

Conditions: Solid Tumor, Unspecified, Adult
NCT03992326

Recruiting

Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors

Conditions: Solid Tumor, Adult
NCT03991741

Not yet recruiting

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

Conditions: Metastatic Melanoma; Locally Advanced Refractory/Recurrent Melanoma; Metastatic Head and Neck Cancer; Locally Advanced Refractory/Recurrent Head and Neck Cancer
NCT03970954

Not yet recruiting

Low-dose Interleukin-2 in Women With Unexplained Miscarriages

Conditions: Recurrent Miscarriage
NCT03970382

Recruiting

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

Conditions: Solid Tumor
NCT03958383

Recruiting

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

Conditions: Melanoma
NCT03952078

Recruiting

A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

Conditions: T-cell Lymphoma
NCT03935347

Withdrawn

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Conditions: Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis Urothelial Carcinoma; Metastatic Ureter Urothelial Carcinoma; Metastatic Urethral Urothelial Carcinoma; Unresectable Renal Pelvis Urothelial Carcinoma; Unresectable Ureter Urothelial Carcinoma
NCT03928275

Not yet recruiting

The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma

Conditions: Cutaneous Metastatic Melanoma
NCT03891706

Recruiting

Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors

Conditions: Solid Tumor
NCT03875079

Recruiting

A Study To Evaluate Safety And Therapeutic Activity Of RO6874281 In Combination With Pembrolizumab, In Participants With Advanced Or Metastatic Melanoma

Conditions: Metastatic Melanoma
NCT03862833

Recruiting

Zoledronic Acid in Combination With Interleukin-2 to Expand Vγ9Vδ2 T Cells After T-replete Haplo-identical Allotransplant

Conditions: Hematopoietic Stem Cell Transplantation
NCT03861793

Recruiting

A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

Conditions: Advanced Solid Tumors
NCT03789006

Recruiting

Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation

Conditions: Kidney Transplant Rejection
NCT03782636

Recruiting

Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)

Conditions: Type1 Diabetes
NCT03778619

Active, not recruiting

MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin

Conditions: Relapsed Non Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma
NCT03739710

Recruiting

Phase II Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Non-small Cell Lung Cancer (NSCLC)

Conditions: Neoplasms
NCT03705403

Recruiting

IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study

Conditions: NSCLC Stage IV; Metastatic Disease
NCT03691376

Recruiting

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions: Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Platinum-Sensitive Fallopian Tube Carcinoma; Platinum-Sensitive Ovarian Carcinoma; Platinum-Sensitive Primary Peritoneal Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Refractory Fallopian Tube Carcinoma; Refractory Ovarian Carcinoma; Refractory Primary Peritoneal Carcinoma
NCT03686124

Recruiting

TCR-engineered T Cells in Solid Tumors

Conditions: Refractory Cancer; Recurrent Cancer; Solid Tumor, Adult; Cancer

COOKIE SETTINGS

Search clinical trials for: Interleukin-2